Oric Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M |
| Operating expenses | $143.0M | $142.9M | $110.8M | $91.8M | $78.9M |
| Cash from operations | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M |
| Capital expenditure | $712,000 | $1.2M | $849,000 | $2.1M | $939,000 |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M |
Shares outstanding 103.5M · Free float 89.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.